Screening and identification of an anti-PD-1 nanobody with antitumor activity

Blocking of programmed death protein 1 (PD-1) or its ligand PD-L1 with corresponding antibody to enhance T-cell response and mediate antitumor activity has been successfully applied in clinical practice. Several immune checkpoint inhibitors including monoclonal antibodies (mAbs) targeting PD-1 have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanting, Yang, Shaoqi, Jiang, Dan, Li, Yanning, Ma, Shuo, Wang, Liyan, Li, Guangqi, Wang, Hongxia, Zhang, Aijun, Xu, Guangxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2023
Materias:
Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867944/
https://www.ncbi.nlm.nih.gov/pubmed/36475449
http://dx.doi.org/10.1042/BSR20221546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867944/
https://www.ncbi.nlm.nih.gov/pubmed/36475449
http://dx.doi.org/10.1042/BSR20221546

Ejemplares similares